Botulinum toxin type B in the management of dystonia non-responsive to botulinum toxin type A;Toxina botulínica tipo B no manejo de distonia não-responsiva a toxina botulínica tipo A

Arquivos de Neuro-Psiquiatria

Volumn 61, Issue 3 A, 2003, Pages 607-610

  Cardoso, Francisco ^a,b  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b Clinica de Disturbios do Movimento   (Brazil)

Author keywords

Botulinum toxin type A; Botulinum toxin type B; Dystonia; Neutralizing antibodies

Indexed keywords

BOTULINUM TOXIN A; BOTULINUM TOXIN B;

ADULT; AGED; ARTICLE; BLEPHAROSPASM; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DYSTONIA; FEMALE; FOLLOW UP; GILLES DE LA TOURETTE SYNDROME; HUMAN; LABORATORY TEST; MALE; PAIN; PTOSIS; TREATMENT OUTCOME; XEROSTOMIA;

EID: 0043195959     PISSN: 0004282X     EISSN: None     Source Type: Journal    
DOI: 10.1590/s0004-282x2003000400015     Document Type: Article

References (12)

1. Jankovic J, Schwartz K. Response and immunoresistance to botulinum toxin injections. Neurology 1995;45:1743-1746.
2. Setler P. The biochemistry of botulinum toxin type B. Neurology 2000;55(Suppl 5):S22-28.
3. Lew MF, Brashear A, Factor S. The safety and efficacy of botulinum toxin type B in the treatment of patients with cervical dystorda: summary of three controlled clinical trials. Neurology 2000;55(Suppl 5):S29-35.
4. Jankovic J, Brin MF. Therapeutic uses of botulinum toxin. N Engl J Med 1991;324:1186-1194.
5. Hanna PA, Jankovic J. Mouse bioassay versus Western blot assay for botulinum toxin antibodies: correlation with clinical response. Neurology 1998;50:1624-1629.
6. Hanna PA, Jankovic J, Vincent A. Comparison of mouse bioassay and immunoprecipitation assay for botulinum toxin antibodies. J Neurol Neurosurg Psychiatry 1999;66:612-616.
7. Sankhla C, Jankovic J, Duane D. Variability of the immunologic and clinical response in dystonic patients immunoresistant to botulinum toxin injections. Mov Disord 1998;13:150-154.
8. Dressler D, Zettl U, Benecke R, Bigalke H. Can intravenous immunoglobulin improve antibody-mediated botulinum toxin therapy failure? Mov Disord 2000;15:1279-1281.
9. Cardoso F, Jankovic J. Dystonia and dyskinesia. Psychiatr Clin N Am 1997;20:821-838.
10. Munchau A, Palmer JD, Dressler D, et al. Prospective study of selective peripheral denervation for botulinum-toxin resistant patients with cervical dystonia. Brain 2001;124:769-783.
11. Bereznai B, Steude U, Seelos K, Botzel K. Chroinc high-frequency globus pallidus internus stimulation in different types of dystonia: a clinical, video, and MRI report of six patients presenting with segmental, cervical, and generalized dystonia. Mov Disord 2002;17:138-144.
12. Lowe NJ, Yamauchi PS, Lask GP, Patnaik R, Moore D. Botulinum toxins types A and B for brow furrows: preliminary experiences with type B toxin dosing. J Cosmet Laser Ther 2002;4:15-18.